[N-23C-2] OFS Capital Corporation SEC Filing

Rhea-AI Filing Summary

Heron Therapeutics (HRTX) – Form 4 filing

On 19 Jul 2025, CEO & Director Craig A. Collard acquired 13,797 common shares through the vesting and settlement of an equal number of restricted stock units (RSUs) granted 19 Jan 2024. The RSUs, which carry a $0 exercise price, vest in 16 equal quarterly tranches; this filing records the fourth installment. Following the transaction Collard’s direct ownership increased to 439,749 common shares, while 137,969 RSUs remain outstanding. No shares were sold or transferred, and no option exercises or cash proceeds were reported.

The transaction is routine insider equity vesting that modestly lifts insider ownership but does not reflect a discretionary open-market purchase or sale. Market impact is expected to be minimal.

Insights

Securities Analyst

TL;DR – Routine RSU vesting; immaterial ownership change.

The CEO’s 13.8k-share acquisition stems from automatic quarterly RSU vesting, not an elective purchase. His stake rises to ~440k shares plus 138k unvested units, adding far less than 1% to the roughly 112 million share base. Because no shares were sold and no cash changed hands, supply-demand dynamics and corporate liquidity remain unaffected. As such, the filing represents standard compensation mechanics with negligible valuation implications for investors.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

NOTIFICATION OF REDEMPTION OF SECURITIES PURSUANT TO RULE 23C-2

UNDER THE INVESTMENT COMPANY ACT OF 1940

File No. 814-00813

OFS CAPITAL CORPORATION

(Name of Registrant)

222 W. Adams Street, Suite 1850

Chicago, Illinois 60606
(Address of Principal Executive Office)

The undersigned here notifies the Securities and Exchange Commission (the “Commission”) that it intends to redeem securities of which it is the issuer, as set forth below in accordance with the requirements of Rule 23c-2 under the Investment Company Act of 1940, as amended.

(1)Title of the class of securities of OFS Capital Corporation (the “Company”) to be redeemed:

4.75% Notes due 2026 (CUSIP: 67103B AA8) (the “Notes”).

(2)Date on which the securities are to be redeemed:

The Notes will be redeemed on August 21, 2025 (the “Redemption Date”).

(3)Applicable provisions of the governing instrument pursuant to which the securities are to be redeemed:

The Notes are to be redeemed pursuant to (i) Section 1101 of the Company’s base indenture governing the Notes, dated as of April 16, 2018 (the “Base Indenture”), between the Company and U.S. Bank Trust Company, National Association (formerly known as U.S. Bank National Association) (“U.S. Bank”), as trustee, and (ii) Section 1.01(h) of the Fifth Supplemental Indenture, dated as of February 10, 2021, between the Company and U.S. Bank, as trustee (the “Fifth Supplemental Indenture”).

(4)The principal amount or number of shares and the basis upon which the securities to be redeemed are to be selected:

The Company will redeem a portion of the outstanding Notes ($69,000,000 aggregate principal amount) pursuant to the terms of the Base Indenture and the Fifth Supplemental Indenture.

SIGNATURE

Pursuant to the requirements of Rule 23c-2 under the Investment Company Act of 1940, as amended, the Company has duly caused this Notice of Intention to Redeem Securities to be signed on its behalf by the undersigned on this 22nd day of July, 2025.

			OFS CAPITAL CORPORATION
			By:			/s/ Bilal Rashid
						Name: Bilal Rashid
						Title: Chief Executive Officer